Eos SENOLYTIX presented preclinical results for its MitoXcel™ geropeptide PTC-2105, demonstrating significant muscle mass gains, fat reduction, and improved physical function in aging models. Unlike GLP-1 therapies, PTC-2105 prevents rapid weight regain and targets aging biology by improving mitochondrial function and clearing senescent cells. The treatment also showed increased overall and cancer-specific survival in mice, highlighting its potential as a first-in-class gerotherapeutic for obesity, sarcopenia, and age-related diseases. Eos plans to advance this therapy through clinical milestones following its upcoming merger with Pulmatrix, expected in Q3 2026.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
Gnosis (GNO) surged 13% in 24 hours, closing in on overtaking BONK by market capitalization to reach the 100th largest token spot. GNO's market cap stands at $303.88 million versus BONK's $330.07 million, requiring a price rise to about $125.48 for t...
Broadridge's Tokenization Pulse Survey shows 84% of firms view tokenization as strategically important, with 68% expecting it to reshape markets within 3-5 years. Most firms plan to integrate tokenization into existing infrastructure rather than buil...
Standard Chartered has partnered with Broadcom to modernize its global banking infrastructure by adopting a secure, resilient private cloud using VMware Cloud Foundation. This upgrade supports critical banking services across 54 markets with enhanced...
